featured
Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
N. Engl. J. Med 2021 Oct 21;385(17)1547-1558, SM Francque, P Bedossa, V Ratziu, QM Anstee, E Bugianesi, AJ Sanyal, R Loomba, SA Harrison, R Balabanska, L Mateva, N Lanthier, N Alkhouri, C Moreno, JM Schattenberg, D Stefanova-Petrova, L Vonghia, R Rouzier, M Guillaume, A Hodge, M Romero-Gómez, P Huot-Marchand, M Baudin, MP Richard, JL Abitbol, P Broqua, JL Junien, MF AbdelmalekFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.